Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DEXCOM INCDXCM · Entity 3114 | EVP Chief Commercial Officer | March 23, 2021 | March 25, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DEXCOM INC
Report date March 23, 2021 · Filed March 25, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Indirectby Trust | 6,654 |
Last balance in matching sequence
After 2021-03-23 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
5 source rowsRow 1 · 2021-03-23 · Sale · Disposed 18 · Balance 7,745 F1: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Row 2 · 2021-03-23 · Sale · Disposed 74 · Balance 7,671 F1: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Row 3 · 2021-03-23 · Sale · Disposed 655 · Balance 7,016 F1: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3: This transaction was executed in multiple trades at prices ranging from $359.70 to $360.67. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Row 4 · 2021-03-23 · Sale · Disposed 268 · Balance 6,748 F1: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4: This transaction was executed in multiple trades at prices ranging from $360.94 to $361.83. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Row 5 · 2021-03-23 · Sale · Disposed 94 · Balance 6,654 F1: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. |
| Common StockSEC Table I · non-derivative | Direct | 21,554 |
Reported balance
Holding disclosure · report date 2021-03-23 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 21,554 |
Filing footnotes · ownership attribution and instrument terms
F1: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan.
F2: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee.
F3: This transaction was executed in multiple trades at prices ranging from $359.70 to $360.67. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
F4: This transaction was executed in multiple trades at prices ranging from $360.94 to $361.83. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 23, 2020 Filed Mar 25, 2020 22:10 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,300 | $209.55 | $272,415.00 |
DisclosureSEC source: 0001093557-20-000109 · edgardoc.xml · nonDerivative · entry 3 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 9,183 F3 · shares: On June 3, 2019, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| March 23, 2020 Filed Mar 25, 2020 22:10 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 231 | $207.71 | $47,980.69 |
DisclosureSEC source: 0001093557-20-000109 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 10,483 F3 · shares: On June 3, 2019, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $207.28 to $208.12. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F5 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| March 13, 2020 Filed Mar 25, 2020 22:10 UTC | DEXCOM INC DXCM · Entity 3114 | GiftCommon Stock | 523 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-20-000109 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,482 F1 · shares: The transaction represents a gift by the Reporting Person of 523 shares to a charitable donor advised fund. F2 · balance_after: Included in this number are 35,492 unvested restricted stock units, 11,748 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 10,910 of which were granted on March 8, 2019 and shall vest through March 8, 2022 and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| March 11, 2020 Filed Mar 14, 2020 01:36 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 7,974 | $265.43 | $2,116,506.92 |
DisclosureSEC source: 0001093557-20-000107 · edgardoc.xml · nonDerivative · entry 3 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,005 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · balance_after: Included in this number are 35,492 unvested restricted stock units, 11,748 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 10,910 of which were granted on March 8, 2019 and shall vest through March 8, 2022 and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| March 11, 2020 Filed Mar 14, 2020 01:36 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 189 | $250.02 | $47,253.78 |
DisclosureSEC source: 0001093557-20-000107 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,979 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $250.02 to $250.0201. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 35,492 unvested restricted stock units, 11,748 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 10,910 of which were granted on March 8, 2019 and shall vest through March 8, 2022 and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| March 11, 2020 Filed Mar 14, 2020 01:36 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 140 | $245.71 | $34,399.55 |
DisclosureSEC source: 0001093557-20-000107 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,168 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $245.62 to $246.3512. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 35,492 unvested restricted stock units, 11,748 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 10,910 of which were granted on March 8, 2019 and shall vest through March 8, 2022 and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| March 08, 2020 Filed Mar 10, 2020 23:40 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 11,748 | $0.00 | $11.75 |
DisclosureSEC source: 0001093557-20-000068 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,308 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 35,492 unvested restricted stock units, 11,748 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 10,910 of which were granted on March 8, 2019 and shall vest through March 8, 2022 and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:31 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 88 | $283.09 | $24,912.00 |
DisclosureSEC source: 0001093557-20-000041 · edgardoc.xml · nonDerivative · entry 4 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 10,714 F1 · shares: On June 3, 2019, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $283.07 to $283.53. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:31 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 125 | $278.61 | $34,826.25 |
DisclosureSEC source: 0001093557-20-000041 · edgardoc.xml · nonDerivative · entry 3 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 10,802 F1 · shares: On June 3, 2019, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:31 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 852 | $278.03 | $236,882.41 |
DisclosureSEC source: 0001093557-20-000041 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 10,927 F1 · shares: On June 3, 2019, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $277.475 to $278.27. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:31 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 467 | $275.99 | $128,886.54 |
DisclosureSEC source: 0001093557-20-000041 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 11,779 F1 · shares: On June 3, 2019, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $275.585 to $276.12. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 22:13 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 500 | $236.09 | $118,044.00 |
DisclosureSEC source: 0001093557-20-000015 · edgardoc.xml · nonDerivative · entry 3 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 12,246 F1 · shares: On June 3, 2019, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $236.00 to $236.40. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 22:13 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 300 | $234.26 | $70,278.00 |
DisclosureSEC source: 0001093557-20-000015 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 12,746 F1 · shares: On June 3, 2019, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $234.06 to $234.52. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 22:13 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 732 | $233.17 | $170,681.46 |
DisclosureSEC source: 0001093557-20-000015 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,046 F1 · shares: On June 3, 2019, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $232.53 to $233.40. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| December 23, 2019 Filed Dec 24, 2019 00:42 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 202 | $213.61 | $43,149.58 |
DisclosureSEC source: 0001093557-19-000262 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,778 F1 · shares: On June 3, 2019, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $213.55 to $213.79. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| December 23, 2019 Filed Dec 24, 2019 00:42 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,331 | $212.93 | $283,407.97 |
DisclosureSEC source: 0001093557-19-000262 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,980 F1 · shares: On June 3, 2019, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $212.55 to $213.45. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| November 22, 2019 Filed Nov 26, 2019 00:43 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 233 | $218.52 | $50,915.39 |
DisclosureSEC source: 0001093557-19-000249 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 15,311 F1 · shares: On June 3, 2019, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $218.11 to $218.33. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| November 22, 2019 Filed Nov 26, 2019 00:43 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,300 | $217.39 | $282,604.01 |
DisclosureSEC source: 0001093557-19-000249 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 15,544 F1 · shares: On June 3, 2019, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $217.06 to $217.47. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| October 23, 2019 Filed Oct 25, 2019 20:35 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 100 | $153.34 | $15,334.00 |
DisclosureSEC source: 0001093557-19-000227 · edgardoc.xml · nonDerivative · entry 5 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 16,844 F4 · shares: On June 3, 2019, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| October 23, 2019 Filed Oct 25, 2019 20:35 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 800 | $152.71 | $122,167.84 |
DisclosureSEC source: 0001093557-19-000227 · edgardoc.xml · nonDerivative · entry 4 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 16,944 F4 · shares: On June 3, 2019, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $152.31 to $153.14. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| October 23, 2019 Filed Oct 25, 2019 20:35 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 633 | $151.70 | $96,028.51 |
DisclosureSEC source: 0001093557-19-000227 · edgardoc.xml · nonDerivative · entry 3 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 17,744 F4 · shares: On June 3, 2019, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $151.18 to $152.16. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| October 07, 2019 Filed Oct 25, 2019 20:35 UTC | DEXCOM INC DXCM · Entity 3114 | OtherCommon Stock | 18,377 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-19-000227 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 18,377 F1 · shares: Shares were transferred from direct ownership to ownership under the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| October 07, 2019 Filed Oct 25, 2019 20:35 UTC | DEXCOM INC DXCM · Entity 3114 | OtherCommon Stock | 18,377 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-19-000227 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,444 F1 · shares: Shares were transferred from direct ownership to ownership under the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. F2 · balance_after: Included in this number are 40,201 unvested restricted stock units, 16,365 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 4,585 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| September 24, 2019 Filed Sep 27, 2019 00:42 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 519 | $155.57 | $80,742.75 |
DisclosureSEC source: 0001093557-19-000219 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 0 F1 · shares: On June 1, 2018, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $155.39 to $156.10. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| September 24, 2019 Filed Sep 27, 2019 00:42 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,497 | $154.80 | $231,739.04 |
DisclosureSEC source: 0001093557-19-000219 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 519 F1 · shares: On June 1, 2018, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $154.24 to $155.23. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| September 09, 2019 Filed Sep 12, 2019 01:28 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 5,525 | $150.11 | $829,363.83 |
DisclosureSEC source: 0001093557-19-000193 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,821 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · balance_after: Included in this number are 40,201 unvested restricted stock units, 16,365 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 4,585 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| September 09, 2019 Filed Sep 12, 2019 01:28 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 318 | $145.38 | $46,230.62 |
DisclosureSEC source: 0001093557-19-000193 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,346 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $145.34 to $145.41. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 40,201 unvested restricted stock units, 16,365 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 4,585 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| August 23, 2019 Filed Aug 27, 2019 01:12 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 896 | $175.88 | $157,585.79 |
DisclosureSEC source: 0001093557-19-000186 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 2,016 F1 · shares: On June 1, 2018, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $175.63 to $176.04. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| August 23, 2019 Filed Aug 27, 2019 01:12 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,120 | $174.56 | $195,502.05 |
DisclosureSEC source: 0001093557-19-000186 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 2,912 F1 · shares: On June 1, 2018, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $174.22 to $174.98. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| July 23, 2019 Filed Jul 24, 2019 22:15 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 836 | $154.99 | $129,569.80 |
DisclosureSEC source: 0001093557-19-000173 · edgardoc.xml · nonDerivative · entry 3 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 4,032 F1 · shares: On June 1, 2018, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $154.90 to $155.14. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| July 23, 2019 Filed Jul 24, 2019 22:15 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 200 | $153.78 | $30,755.00 |
DisclosureSEC source: 0001093557-19-000173 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 4,868 F1 · shares: On June 1, 2018, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $153.76 to $153.79. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| July 23, 2019 Filed Jul 24, 2019 22:15 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 980 | $152.29 | $149,245.57 |
DisclosureSEC source: 0001093557-19-000173 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 5,068 F1 · shares: On June 1, 2018, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $152.09 to $152.66. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| June 24, 2019 Filed Jun 25, 2019 21:21 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 592 | $151.09 | $89,447.65 |
DisclosureSEC source: 0001093557-19-000167 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 6,048 F1 · shares: On June 1, 2018, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $150.83 to $151.55. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| June 24, 2019 Filed Jun 25, 2019 21:21 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,424 | $149.00 | $212,178.14 |
DisclosureSEC source: 0001093557-19-000167 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 6,640 F1 · shares: On June 1, 2018, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $148.42 to $149.40. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| May 23, 2019 Filed May 24, 2019 21:09 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,100 | $117.65 | $129,410.05 |
DisclosureSEC source: 0001093557-19-000128 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 8,064 F1 · shares: On June 1, 2018, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $117.50 to $117.70. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| May 23, 2019 Filed May 24, 2019 21:09 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 916 | $116.86 | $107,041.84 |
DisclosureSEC source: 0001093557-19-000128 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 9,164 F1 · shares: On June 1, 2018, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $116.46 to $117.13. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| April 23, 2019 Filed Apr 24, 2019 23:58 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,200 | $117.27 | $140,724.00 |
DisclosureSEC source: 0001093557-19-000110 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 10,080 F1 · shares: On June 1, 2018, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $117.25 to $117.49. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| April 23, 2019 Filed Apr 24, 2019 23:58 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 816 | $116.56 | $95,114.02 |
DisclosureSEC source: 0001093557-19-000110 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 11,280 F1 · shares: On June 1, 2018, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $116.25 to $117.00. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| March 25, 2019 Filed Mar 27, 2019 21:40 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,400 | $127.77 | $178,884.44 |
DisclosureSEC source: 0001093557-19-000091 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 12,096 F1 · shares: On June 1, 2018, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $127.01 to $128.00. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 51,203 unvested restricted stock units, 16,365 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 9,170 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| March 25, 2019 Filed Mar 27, 2019 21:40 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 616 | $126.47 | $77,904.97 |
DisclosureSEC source: 0001093557-19-000091 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,496 F1 · shares: On June 1, 2018, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $126.01 to $127.00. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 51,203 unvested restricted stock units, 16,365 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 9,170 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| March 12, 2019 Filed Mar 13, 2019 23:00 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,191 | $142.79 | $312,857.71 |
DisclosureSEC source: 0001093557-19-000080 · edgardoc.xml · nonDerivative · entry 3 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,570 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 12, 2019 Filed Mar 13, 2019 23:00 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 6,399 | $142.79 | $913,727.29 |
DisclosureSEC source: 0001093557-19-000080 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,761 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 51,203 unvested restricted stock units, 16,365 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 9,170 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| March 12, 2019 Filed Mar 13, 2019 23:00 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,221 | $142.79 | $317,141.48 |
DisclosureSEC source: 0001093557-19-000080 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,160 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 51,203 unvested restricted stock units, 16,365 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 9,170 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 00:30 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 16,365 | $0.00 | $16.37 |
DisclosureSEC source: 0001093557-19-000051 · wf-form4_155235063585618.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,381 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock. F2 · balance_after: Included in this number are 51,203 unvested restricted stock units, 16,365 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 9,170 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| December 21, 2018 Filed Dec 27, 2018 01:33 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 310 | $110.61 | $34,287.74 |
DisclosureSEC source: 0001093557-18-000258 · edgardoc.xml · nonDerivative · entry 3 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 14,112 F1 · shares: On June 1, 2018, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $110.40 to $111.08. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| December 21, 2018 Filed Dec 27, 2018 01:33 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 700 | $109.57 | $76,699.98 |
DisclosureSEC source: 0001093557-18-000258 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 14,422 F1 · shares: On June 1, 2018, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $109.38 to $109.82. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| December 21, 2018 Filed Dec 27, 2018 01:33 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 500 | $108.23 | $54,113.10 |
DisclosureSEC source: 0001093557-18-000258 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 15,122 F1 · shares: On June 1, 2018, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $108.00 to $108.59. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| November 23, 2018 Filed Nov 27, 2018 23:27 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,236 | $122.00 | $150,794.97 |
DisclosureSEC source: 0001093557-18-000244 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 15,622 F1 · shares: On June 1, 2018, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $122.00 to $122.04. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| November 23, 2018 Filed Nov 27, 2018 23:27 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 500 | $119.74 | $59,869.00 |
DisclosureSEC source: 0001093557-18-000244 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 16,858 F1 · shares: On June 1, 2018, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $119.64 to $120.13. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| October 23, 2018 Filed Oct 26, 2018 00:59 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 100 | $129.78 | $12,978.00 |
DisclosureSEC source: 0001093557-18-000223 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 17,358 F1 · shares: On June 1, 2018, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.